Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Caesars Entertainment Inc (CZR) vs Nuwellis Inc (NUWE) Price & Performance

Caesars Entertainment IncTrade
Nuwellis IncTrade

Price performance (Past 24H)

Key statistics

Caesars Entertainment Inc vs Nuwellis Inc — how do they compare? Caesars Entertainment Inc trades at $29.49 (market cap $6.02B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Caesars Entertainment Inc is far larger — about 2736.4× Nuwellis Inc's market cap, and Caesars Entertainment Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Caesars Entertainment Inc for 31 Days and Nuwellis Inc for 26 Days on average.

CZRNUWE
Market Cap
$6.02B$2.20M
Volume
6,412,151121,544
Sector
Consumer CyclicalHealth
52-Week High
$30.41$146.65
52-Week Low
$18.14$0.68
Typical Hold Time
31 Days26 Days
Enterprise Value
$29.91B-$1.52M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Caesars Entertainment Inc

CZR trades at $29.50, up slightly by 0.03% today, with a bearish technical signal and neutral oscillators. The company reported a net loss of $502 million in 2025, missing earnings estimates for three consecutive quarters, while revenue remains stable near $11.5 billion. A pending merger with Fertitta Entertainment at $31.00 per share is under regulatory review, with several law firms investigating the deal's fairness.

CZR faces headwinds from persistent losses and high debt, but the merger offer provides a near-term price floor. Upside depends on operational turnaround and deal approval, while risks include earnings volatility and regulatory hurdles. Analyst consensus is mixed, with a hold-heavy rating and a $30.75 price target slightly above current levels.

Nuwellis Inc

NUWE trades at $0.689, down 0.25% with a bearish technical signal despite oversold RSI readings. The company shows promising revenue growth (14% YoY in Q2 2026) and strong gross margins (69.69%), but faces significant profitability challenges with a -125.63% net income margin and negative cash flow. Recent news highlights console adoption growth and strategic expansions in pediatric care.

While NUWE's valuation metrics appear attractive (P/E 0.03, P/S 0.01), the company's persistent losses and negative cash flow present substantial risk. Analyst sentiment is mixed with a 50/50 buy/hold split. The stock offers speculative potential if management can achieve profitability, but requires careful risk assessment given current financial challenges.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CZR

No sentiment data available yet.

NUWE
2% Buy98% Sell
Avg holding period · 26 Days

Top news

Latest headlines on both assets

About Caesars Entertainment Inc

Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.

Read more on CZR →

About Nuwellis Inc

Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.

Read more on NUWE →